With the rapidly evolving nature of the coronavirus (COVID-19) pandemic, configurability and adaptability are key for IRT systems in order to minimise the impact to clinical trial patients. It is important to directly communicate with customers to help them mitigate the increasing challenges and avoid interruptions to their ongoing trials. Kelly Knowles at Signant Health summarises her findings and best practices, in order to share with the industry at large.